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felBACKGROUND There has been conﬂicting clinical evidence as to the inﬂuence of female sex on outcomes after
transcatheter aortic valve replacement.
OBJECTIVES The aim of this study was to evaluate the impact of sex on early and late mortality and safety end points
after transcatheter aortic valve replacement using a collaborative meta-analysis of patient-level data.
METHODS From the MEDLINE, Embase, and the Cochrane Library databases, data were obtained from 5 studies, and a
database containing individual patient-level time-to-event data was generated from the registry of each selected study.
The primary outcome of interest was all-cause mortality. The safety end point was the combined 30-day safety end
points of major vascular complications, bleeding events, and stroke, as deﬁned by the Valve Academic Research Con-
sortium when available.
RESULTS Five studies and their ongoing registry data, comprising 11,310 patients, were included. Women constituted
48.6% of the cohort and had fewer comorbidities than men. Women had a higher rate of major vascular complications
(6.3% vs. 3.4%; p < 0.001), major bleeding events (10.5% vs. 8.5%; p ¼ 0.003), and stroke (4.4% vs. 3.6%; p ¼ 0.029)
but a lower rate of signiﬁcant aortic incompetence (grade $2; 19.4% vs. 24.5%; p < 0.001). There were no differences in
procedural and 30-day mortality between women and men (2.6 % vs. 2.2% [p ¼ 0.24] and 6.5% vs. 6.5% [p ¼ 0.93],
respectively), but female sex was independently associated with improved survival at median follow-up of 387 days
(interquartile range: 192 to 730 days) from the index procedure (adjusted hazard ratio: 0.79; 95% conﬁdence interval:
0.73 to 0.86; p ¼ 0.001).
CONCLUSIONS Although women experience more bleeding events, as well as vascular and stroke complications,
female sex is an independent predictor of late survival after transcatheter aortic valve replacement. This should be taken
into account during patient selection for this procedure. (J Am Coll Cardiol 2015;66:221–8) © 2015 by the American
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222T ranscatheter aortic valve replace-ment (TAVR) is the new standard ofcare for patients with symptomatic
aortic stenosis who are deemed to have
high or prohibitive surgical risk, with
>80,000 procedures performed to date in
>40 countries worldwide (1,2). The currentevidence with regard to the impact of sex on out-
comes in TAVR is insufﬁcient and conﬂicting, with
some studies reporting improved mid- to long-term
survival in women (3–5) and other studies demon-
strating similar or worse survival compared with
men (6,7). This remains an overall unresolved and
poorly described issue that has signiﬁcant implica-
tions with regard to patient selection for this proce-
dure. Therefore, to evaluate the inﬂuence of sex on
clinical outcomes in high-risk patients undergoing
TAVR, we performed a collaborative meta-analysis
of individual patient-level data.SEE PAGE 229METHODS
STUDY COHORT. We conducted searchers of the
Cochrane Controlled Trials Registry and MEDLINE
and Embase databases for reports published from
January 2002 through June 2014 using the following
pre-deﬁned search terms: transcatheter aortic valve
implantation/replacement and outcome or gender or
sex. We restricted our analysis to published data.
References from reviews and selected reports
were also examined for potential relevant citations.
No language restrictions were applied. Studies
were selected by 2 independent reviewers (S.A.O.,
M.-C.M.).
We restricted our analysis to trials that met all of
the following inclusion criteria: 1) inclusion of pa-
tients with severe aortic valve stenosis undergoing
TAVR via the transfemoral, transapical, transaortic,
transcarotid, or transsubclavian approach; 2) either a
single-group cohort or a controlled comparison be-
tween TAVR and surgical aortic valve replacement
through random or nonrandom allocation; and 3)
available data on at least short-term (30-day or in-
hospital) and 1-year all-cause mortality. Randomized
controlled trials, registries, and pre-speciﬁed sub-
groups of studies reporting TAVR data were consid-
ered for analysis. Full-text articles were included.a and additional industry support for annual cardiovascular mee
ships relevant to the contents of this paper to disclose.Susheel
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Va
received February 3, 2015; revised manuscript received March 2Exclusion criteria were duplicate reports, unpub-
lished meeting abstracts and studies with <200 pa-
tients, and studies that did not perform multivariable
adjustment. The quality of randomized controlled
trials included in the meta-analysis was assessed
for descriptive purpose using the Jadad score for
randomized controlled trials and the quality of non-
randomized studies (8) using the Newcastle-Ottawa
Scale for cohort studies (Online Table 1). A database
containing individual patient-level time-to-event
data was generated from the registry of each of the
studies selected.
DEFINITIONS AND ENDPOINTS. The primary efﬁ-
cacy end point was mortality from any cause at
longest follow-up. The safety end point was the
combined 30-day safety end points, as deﬁned by
the individual studies and by the Valve Academic
Research Consortium when used, of major vascular
complications, bleeding, stroke, and myocardial
infarction (9). The secondary end points were the
individual safety end points of the combined Valve
Academic Research Consortium safety end point
and device success, which was deﬁned as success-
ful vascular access, delivery, and deployment of
1 prosthesis and correct position and performance
of the prosthetic valve. Other secondary end
points included all-cause mortality at 1- and 2-year
follow-up.
STATISTICAL ANALYSIS. A database containing
individual patient-level, time-to-event data was
generated from the registry of each of the studies
selected. The primary analysis was performed on all
patients. Pre-speciﬁed analyses were performed on
the subgroups according to valve type (the balloon-
expandable SAPIEN [Edwards Lifesciences, Irvine,
California] or the self-expandable CoreValve [Med-
tronic, Dublin, Ireland]) and access (femoral or api-
cal). Categorical variables were compared using
chi-square or Fisher exact tests. Continuous variables
are reported as mean  SD and were compared using
Student t tests. For variables that were not normally
distributed, Wilcoxon tests were used to compare
groups. Time-to-event data are reported and dis-
played using the Kaplan-Meier method, with com-
parisons between groups performed using log-rank
tests. Cumulative survival curves by sex were con-
structed using the Kaplan-Meier method. A stepwisetings. All other authors have reported that they have
Kodali, MD, served as Guest Editor for this paper.
lentin Fuster.
7, 2015, accepted May 7, 2015.
FIGURE 1 Study Selection
525 abstracts identified through electronic
database searching
520 abstracts after duplicates removed
520 abstracts screened
17 full-text articles
assessed for eligibility
6 studies selected and
their authors contacted
for individual patient
data
5 registries supplied
individual patient-level
data (3,7,19-21)
504 abstracts excluded
1 study unable to provide
individual patient due to ongoing
local analysis (5)
11 studies excluded
5 studies excluded due to
3 studies with no multivariate
3 low numbers (13-15)
adjustment (16-18)
overlap with chosen studies (4,6,10-12)
A ﬂow diagram of study selection and exclusion is shown (3-7,10-21).
J A C C V O L . 6 6 , N O . 3 , 2 0 1 5 O’Connor et al.
J U L Y 2 1 , 2 0 1 5 : 2 2 1 – 8 Impact of Female Sex on Late Mortality Outcome
223Cox multivariate analysis including all variables with
p values <0.05 in each univariate analysis were used.
Results are presented as hazard ratios with 95%
conﬁdence intervals (CIs). The p value threshold for
statistical signiﬁcance was set at 0.05. Analyses were
conducted using SPSS version 21 (SPSS, Inc., Chicago,
Illinois).
RESULTS
Our search identiﬁed 520 reports (Figure 1), of which
508 were excluded after abstract screening. Of the 17
full-text reports assessed, 5 studies were excluded
because they contained patient data that overlapped
with our selected studies (4,6,10–12), 3 were excluded
because of small sample sizes (n < 200) (13–15), and 3
were excluded because the investigators did not
perform multivariate adjustment and/or reported
30-day follow-up only (16–18). Finally, 6 studies were
selected and the principal investigators contacted
(3,5,7,19–21). Five investigators answered positively,
leaving a total of 5 studies and their registry data,
comprising a total of 11,310 patients, for inclusion in
the analysis (3,7,19–21).
PATIENT POPULATION. The characteristics of the
studies and patient population are described in
Online Table 2. Overall, patients were prospectively
enrolled from January 2005 to December 2012 in 1 of
the 5 international multicenter trials or registries.
The criteria for inclusion are detailed in each indi-
vidual study, but all patients had severe symptom-
atic aortic stenosis and were at high risk or were
ineligible for conventional surgery. TAVR was per-
formed using conventional techniques, as have been
previously described, via the transfemoral, trans-
apical, transsubclavian, transaxillary, and transaortic
approaches. Valves implanted included the SAPIEN
and SAPIEN XT devices in 23-, 26-, and 29-mm sizes
(Edwards Lifesciences); the CoreValve device in
23-, 26-, 29-, and 31–mm sizes (Medtronic); and the
repositionable Portico valve (St. Jude Medical,
St. Paul, Minnesota).
BASELINE CHARACTERISTICS. The baseline clinical
demographics of the patients are presented in Table 1.
Of the 11,310 patients included in the ﬁnal cohort,
48.6% (n ¼ 5,502) were women. Men had a higher rate
of risk factors than women, with a higher prevalence
of diabetes, previous myocardial infarction, previous
percutaneous coronary intervention, previous coro-
nary artery bypass graft surgery, peripheral vascular
disease, poor left ventricular systolic function (left
ventricular ejection fraction <30%), 3-vessel coronary
artery disease, a higher logistic European System
for Cardiac Operative Risk Evaluation score, andpulmonary disease. Women were older, had higher
transvalvular gradients and higher pulmonary artery
pressures, and had smaller annular sizes.
PROCEDURAL CHARACTERISTICS AND OUTCOMES. The
procedural characteristics are presented in Table 1.
The majority of the overall cohort underwent TAVR
via the transfemoral approach, followed by the
transapical and transsubclavian approaches. The
transfemoral approach was more common in women
than in men. Balloon-expandable devices were used
more frequently than self-expandable valves in the
overall cohort, and a higher proportion of women
than men received balloon-expandable valves.
Clinical outcomes are listed in Table 2. In the whole
group, procedural success was achieved in 97% of
patients, irrespective of sex. There was no difference
in the incidence of valve migration or embolization,
conversion to conventional surgery, or procedure-
related death. There was, however, a higher rate of
TABLE 1 Baseline Ch
Age, yrs
BMI, kg/m2
BSA
Myocardial infarction
Any smoking history
Peripheral vascular dise
Diabetes (any)
Previous stroke (CVA)
Previous PCI
CABG
Pulmonary disease
CrCl, ml/min/1.73 m2
Renal insufﬁciency
(CrCl <60 ml/m
Coronary artery disease
1-vessel disease
2-vessel disease
3-vessel disease
LVEF <50%
30% < LVEF < 50%
LVEF <30%
Logistic EuroSCORE
Aortic valve gradient, m
Aortic valve area, cm2
Annular size, mm
PAP, mm Hg
PAP $60 mm Hg
Procedural characterist
Implantation approac
Transapical
Transfemoral
Transsubclavian
Transaxillary
Transaortic and ot
Valve type
CoreValve
SAPIEN
Portico
Valve size (mm)
23
26
29
31
Femoral diameter (left
Femoral diameter (righ
Values are mean  SD or n
BMI ¼ body mass index
brovascular accident; Euro
tricular ejection fraction; P
O’Connor et al. J A C C V O L . 6 6 , N O . 3 , 2 0 1 5
Impact of Female Sex on Late Mortality Outcome J U L Y 2 1 , 2 0 1 5 : 2 2 1 – 8
224major vascular complications and major bleeding
including cardiac tamponade in women. Men had a
signiﬁcantly higher rate of aortic incompetence
(grade >2) and were more likely to need pacemaker
implantation post-procedurally than women.aracteristics
Women
(n ¼ 5,502)
Men
(n ¼ 5,808)
All Patients
(n ¼ 11,310) p Value
83.3  7.5 81.6  8.2 82.4  7.9 <0.001
26.5  6.1 26.6  4.8 26.5  5.5 0.46
1.7  0.2 1.9  0.2 1.8  0.2 <0.001
805 (14.6) 1,657 (28.6) 2,462 (21.8) <0.001
1,204 (21.9) 2,279 (39.3) 3,483 (30.8) <0.001
ase 1,345 (24.5) 2,053 (35.4) 3,398 (30.1) <0.001
1,367 (24.9) 1,713 (29.5) 3,080 (27.2) <0.001
836 (15.2) 992 (17.2) 1,828 (16.2) 0.005
929 (17.6) 1,300 (23.4) 2,229 (20.6) <0.001
771 (14.1) 2,381 (41.1) 3,152 (28) <0.001
1,553 (28.2) 1,824 (31.4) 3,377 (29.9) <0.001
54.1  26 55.6  25.7 54.9  25.9 <0.001
in/1.73 m2)
3,553 (66.1) 3,652 (64.3) 7,205 (65.2) 0.041
2,120 (38.6) 3,319 (57.3) 5,439 (48.2) <0.001
901 (18.8) 986 (19) 1,887 (18.9) 0.80
529 (11) 818 (15.8) 1,347 (13.5) <0.001
519 (10.8) 1,363 (26.3) 1,882 (18.9) <0.001
1,342 (24.4) 2,404 (41.5) 3,746 (33) <0.001
813 (14.8) 1,408 (24.3) 2,221 (19.7) <0.001
251 (4.6) 581 (10) 832 (7.3) <0.001
22.2  13.9 23.9  15.4 23.1  14.7 <0.001
m Hg 61.2  26.7 55.8  23.9 58.4  25.4 <0.001
0.7  1.9 0.8  2.1 0.7  2 <0.001
20.7  3.6 22.8  5.1 21.8  4.5 <0.001
51  18.8 47.4  15 49.2  17.1 <0.001
1,089 (22.1) 869 (16.7) 1,958 (19.3) <0.001
ics
h
1,236 (22.5) 1,353 (23.3) 2,589 (22.9) 0.29
3,874 (70.4) 3,945 (67.9) 7,819 (69.1) 0.004
219 (4) 356 (6.1) 575 (5.1) <0.001
10 (0.2) 6 (0.1) 16 (0.1) 0.27
her 103 (1.9) 93 (1.6) 196 (1.7) 0.27
2,038 (35.2) 1,724 (31.4) 3,762 (33.3) <0.001
3,762 (64.8) 3,736 (67.9) 7,498 (66.3) <0.001
0 (0) 38 (0.7) 38 (0.3) <0.001
2,879 (52.9) 620 (10.8) 3,499 (31.2) <0.001
2,097 (38.5) 3,236 (56.2) 5,333 (47.6) <0.001
449 (8.2) 1,714 (29.8) 2,163 (19.3) <0.001
19 (0.3) 185 (3.2) 204 (1.8) <0.001
), mm 7.2  1.2 7.9  1.4 7.5  1.3 <0.001
t), mm 7.5  1.1 7.7  1.7 7.6  1.4 <0.001
(%).
; CABG ¼ coronary artery bypass grafting; CrCl ¼ creatinine clearance; CVA ¼ cere-
SCORE ¼ European System for Cardiac Operative Risk Evaluation; LVEF ¼ left ven-
CI ¼ percutaneous coronary intervention; PAP ¼ pulmonary artery pressure.PROCEDURAL CHARACTERISTICS AND OUTCOMES
BY VALVE TYPE. In a subanalysis of procedural and
30-day outcomes according to valve type, pacemaker
implantation was signiﬁcantly more common in men
among the patients who received self-expandable
valves (26.4% vs. 19.4%; p < 0.001), but there was
no statistically signiﬁcant difference between the
sexes in the balloon-expandable valve group (9.3%
vs. 8.4%; p ¼ 0.15) (Online Table 3). Valve migration
also was more common in men treated with balloon-
expandable valves (2.5% vs. 0.8%; p ¼ 0.008), but
no statistical difference existed between the sexes in
patients treated with self-expandable valves (1.5% vs.
0.8%; p ¼ 0.067). Likewise, signiﬁcant aortic incom-
petence (grade > 2) occurred more frequently in men
than in women treated with balloon-expandable
valves (5.2% vs. 2.8%; p < 0.001), but there was no
difference between women and men treated with
self-expandable valves (3.4% vs. 2.5%; p ¼ 0.16).
The rate of stroke at 30-day follow-up was higher in
women who received self-expandable valves, but no
difference existed in patients who received
self-expandable valves. However, major vascular
complications and major bleeding were consistently
higher in women regardless of the type of valve
implanted.
ALL-CAUSE MORTALITY. All-cause mortality rates at
30 days were the same in men and women, despite
the differences in baseline risk proﬁles. The median
duration of follow-up was 387 days (interquartile
range: 192 to 730 days) from the index procedure.
The Kaplan-Meier survival curve demonstrates a
signiﬁcant survival advantage for women (log-rank
p < 0.001) (Figure 2). The 1- and 2-year survival
estimates were 82.7% (95% CI: 81.6% to 84.0%) and
74.0% (95% CI: 72.5% to 75.4%), respectively, for
women and 78.2% (95% CI: 77.0% to 79.3%) and
67.8% (95% CI: 66.3 to 69.3%), respectively, for
men.
In the Cox model for all-cause mortality, the
adjusted hazard ratio for female sex was 0.79 (95% CI:
0.73 to 0.86; p < 0.001). The independent predictors
of late mortality are listed in Table 3.
Female sex was consistently associated with
improved survival regardless of valve type and route
of access when subanalyses were performed in these
subgroups (Online Figure 1).
In a subanalysis comparing the predictors of mor-
tality between women and men, both sexes shared
the predictors body mass index, pulmonary disease,
creatinine clearance, aortic incompetence post-
implantation (grade >2), and a nonfemoral approach
(Online Table 4). However, age was a predictor of
mortality in men but not in women.
TABLE 2 Procedural and 30-Day Outcomes
Women
(n ¼ 5,502)
Men
(n ¼ 5,808)
All Patients
(n ¼ 11,310) p Value
Device success 5,341 (97.3) 5,620 (96.9) 10,961 (97.1) 0.22
Conversion to conventional surgery 53 (1) 50 (0.9) 103 (0.9) 0.57
Valve embolization 45 (1) 74 (1.5) 119 (1.2) 0.018
New permanent pacemaker 650 (11.9) 881 (15.3) 1,531 (13.7) <0.001
Cardiac tamponade 71 (1.3) 41 (0.7) 112 (1) 0.002
Major vascular complication 349 (6.3) 195 (3.4) 544 (4.8) <0.001
Aortic incompetence (grade $2) 914 (19.4) 1,243 (24.5) 2,157 (22) <0.001
Aortic incompetence (grade >2) 128 (2.7) 235 (4.6) 363 (3.7) <0.001
Procedure-related death (<72 h) 140 (2.6) 129 (2.2) 269 (2.4) 0.24
All-cause death (30-day) 351 (6.5) 371 (6.5) 722 (6.5) 0.93
Myocardial infarction (30-day) 124 (2.3) 128 (2.2) 252 (2.2) 0.86
Stroke (30-day) 243 (4.4) 210 (3.6) 453 (4) 0.029
Major bleeding (30-day) 379 (10.5) 313 (8.5) 692 (9.5) 0.003
Values are n (%).
FIGURE 2 Kaplan-Meier Plot of All-Cause Mortality
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Women’s survival advantage throughout the follow-up period is depicted.
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We performed a patient-level pooled meta-analysis of
5 prospective studies and their registries including a
total of 11,310 patients. The most important ﬁnding of
our study is that female sex was associated with a
survival advantage compared with male patients,
even after adjustment for baseline demographic and
clinical factors and valve type. There was, however,
no difference between male and female patients with
respect to 30-day mortality (Central Illustration). This
was despite women having higher rates of major
vascular, bleeding, and stroke events.
We observed an almost 2-fold increase in the rate
of vascular complications in women regardless of the
type of valve used. This observation is consistent
with previously published studies (3,6,7), and a
number of factors have been reported to be predictors
of vascular complications after transfemoral TAVR,
including introducer sheath–to–femoral artery ratio
and femoral artery calcium score (22,23). Women
were of smaller stature and had smaller femoral ar-
teries than men in this combined cohort, and this may
explain the higher rate of complications.
Major bleeding at 30 days was signiﬁcantly more
frequent in female patients, an observation that has
also been reported in some other studies (3,6);
however, this ﬁnding has not been consistent across
all studies (7,12). Again, the likely mechanisms for
this are the lower body surface area and older age
of female patients. These data are comparable to
peri–percutaneous coronary intervention bleeding
data, in which female sex is a signiﬁcant risk factor
(24).
To our knowledge, this is the ﬁrst analysis to
demonstrate a signiﬁcantly higher rate of stroke in
women undergoing TAVR (Central Illustration). This is
a somewhat surprising ﬁnding, and it is difﬁcult to
explain given the lower baseline vascular risk
in women. We also demonstrated that this in-
creased stroke risk seems to occur in patients who
receive self-expandable valves but not in those who
receive balloon-expandable valves, without a clear
explanation.
Although female patients had signiﬁcantly higher
rates of adverse events periprocedurally, there was
no impact on short-term mortality, and female pa-
tients continued to show better late survival. There
are some potential mechanisms for the observed
advantage. First, the impact of these periprocedural
events may be less in women compared with men. To
evaluate this, we performed an analysis of the asso-
ciations of these periprocedural events with 30-day
mortality. There were no signiﬁcant differencesbetween women and men with respect to the impact
of major vascular complications (odds ratio [OR]:
2.57; 95% CI: 1.87 to 3.57; p < 0.001 vs. OR: 2.78; 95%
CI: 1.85 to 4.12; p < 0.001) and major bleeding
(OR: 9.64; 95% CI: 7.27 to 12.79; p < 0.001 vs. OR:
10.20; 95% CI: 7.64 to 13.65; p < 0.001).
However, stroke appeared to have a more signiﬁ-
cant impact on short-term mortality in men than in
women (OR: 15.4; 95% CI: 11.59 to 20.48; p < 0.001 vs.
OR: 20.65; 95% CI: 15.30 to 27.87; p < 0.001). This may
in some part explain the lack of sex difference at
30 days despite more procedural events.
TABLE 3 Predictors of Long-Term All-Cause Mortality
Death
(n ¼ 3,072)
No Death
(n ¼ 8,417) p Value
HR (95% CI)
p ValueUnivariate Model Multivariate Model (Cox)
Age, yrs 82.2  8.2 83.1  7.2 <0.001 1.00 (1.00–1.02) 0.002
Women 1,359 (44.2) 4,037 (50.1) <0.001 0.79 (0.72–0.86) 0.79 (0.72–0.87) <0.001
BMI, kg/m2 26.7  5.4 25.9  5.5 <0.001 0.98 (0.98–0.99) <0.001
Previous myocardial infarction 751 (24.5) 1,666 (20.7) <0.001 1.24 (1.13–1.37)
Active smoker 1,102 (35.9) 2,320 (28.8) <0.001
Peripheral vascular disease 1,069 (34.9) 2,287 (28.5) <0.001 1.38 (1.27–1.51) 1.11 (1.01–1.21) 0.026
Diabetes (any) 864 (28.1) 2,174 (27.0) 0.23 1.06 (0.97–1.16)
Previous stroke (CVA) 536 (17.6) 1,260 (15.7) 0.018 1.14 (1.02–1.28)
Previous PCI 658 (23.4) 1,526 (19.4) <0.001 1.27 (1.15–1.41) 0.93 (0.84–1.03) 0.17
CABG 868 (28.3) 2,253 (28.1) 0.82 1.01 (0.92–1.10)
PAP $60 mm Hg 497 (19.3) 1,449 (19.6) 0.70 0.98 (0.87–1.09)
Pulmonary disease 1,070 (34.8) 2,258 (28.0) <0.001 1.37 (1.26–1.50) 1.32 (1.22–1.44) <0.001
CrCl, ml/min/1.73 m2 56.4  26.2 50.8  24.9 <0.001
Renal insufﬁciency
(CrCl <60 ml/min/1.73 m2)
2,138 (70.8) 4,952 (63) <0.001 1.43 (1.30–1.56) 1.22 (1.11–1.35) <0.001
Coronary artery disease 1,587 (51.8) 3,789 (47.1) <0.001 1.21 (1.11–1.31)
LVEF <30% 244 (8.8) 580 (7.5) 0.025 1.19 (1.02–1.40)
EuroSCORE 22.1  14 25.9  15.9 <0.001
Aortic valve gradient, mm Hg 58.4  24.7 57.2  27.0 0.058
Aortic valve area, cm 0.7  1.0 0.8  3.5 0.12
Annular size, mm 21.6  3.0 21.8  5.0 0.82
Femoral diameter (left), mm 7.5  1.3 7.4  1.4 0.59
Femoral diameter (right), mm 7.6  1.4 7.5  1.3 0.063
Transfemoral access 1,911 (62.2) 5,745 (71.3) <0.001 0.66 (0.61–0.72) 0.77 (0.71–0.85) <0.001
Balloon-expandable valve 1,385 (45.1) 3,521 (43.7) 0.18 1.06 (0.97–1.15)
Aortic incompetence (grade $2) 658 (26.1) 1,486 (20.9) <0.001 1.33 (1.20–1.48) 1.74 (1.46–2.07) <0.001
Values are mean  SD or n (%).
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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226Second, although women were older than men,
they had a lower baseline cardiovascular risk proﬁle
and fewer comorbidities. Although the sex difference
in mortality outcomes remained signiﬁcant after
adjustment for these demographic, procedural, and
clinical differences, the potential impact of these
factors and other unidentiﬁed confounders cannot be
underestimated. Furthermore, the recognized longer
life expectancy described in women contributes to
this explanation.
Third, women had a signiﬁcantly lower incidence of
moderate to severe paravalvular aortic incompetence
post-procedurally thanmen, probably because ofmore
frequent undersizing in men due to larger annular
sizes. This appeared to occur more exclusively with
balloon-expandable valves. Post-TAVR aortic regur-
gitation has been shown to be associated with
increased mortality (20,21,25).
Finally, it has been demonstrated that women
adapt differently than men with aortic stenosis, with
higher levels of interstitial ﬁbrosis in men (26) and a
more rapid reversal of myocardial hypertrophy in
women post–surgical aortic valve replacement (27).This may also be 1 reason for the favorable evolution
in female patients post-TAVR.
The evidence for the effect of sex on clinical out-
comes after conventional surgical aortic valve ap-
pears to be conﬂicting. There are some purely surgical
series suggesting better late survival (28), or no dif-
ference (29,30), in women undergoing surgical aortic
valve replacement, but there are more contemporary
studies focusing on older women and high-risk TAVR-
eligible patients that demonstrate worse early (31)
and late (32) outcomes. Indeed, in a retrospective
analysis of the PARTNER (Placement of Aortic
Transcatheter Valves) trial, women appeared to have
better late mortality with TAVR than with surgical
aortic valve replacement (12). Although we cannot
draw deﬁnite conclusions from these data, if further
studies suggest worse outcomes, it may have impor-
tant implications for the choice of procedure for fe-
male patients, suggesting earlier access to TAVR for
women than for men.
STUDY STRENGTHS AND LIMITATIONS. The strength
of this analysis is that it included individual patient-
level data from a large patient population from
CENTRAL ILLUSTRATION Impact of Female Sex on Short- and Long-Term Outcomes in Patients Undergoing TAVR
O’Connor, S.A. et al. J Am Coll Cardiol. 2015; 66(3):221–8.
The Kaplan-Meier curves demonstrate 30-day through 5-year outcomes for men and women who underwent transcatheter aortic valve replacement (TAVR), on the basis
of a collaborative meta-analysis of patient-level data. AI ¼ aortic incompetence/paravalvular leak; PPM ¼ permanent pacemaker implantation.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Although
women undergoing TAVR are subject to higher rates of peripro-
cedural complications, they enjoy favorable mortality outcomes
compared with men.
TRANSLATIONAL OUTLOOK: Future studies should be
directed toward developing advances in device technology and
patient selection to reduce the risk for procedural morbidity
associated with TAVR, particularly for women.
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227multinational, multicenter, randomized and non-
randomized real-world studies. Also, it was ad-
equately powered to assess mortality outcomes. Our
study, however, was subject to selection bias, as we
were able to include data from only 5 of the 6 studies
identiﬁed by our systematic search strategy. Because
this study was an analysis of a global population, we
could not perform a sensitivity analysis. With regard to
the studies included, individual study effect was
adjusted for by introducing the study as a covariate.
Results with and without studies’ factors were similar,
and therefore wemay conclude that the characteristics
of the studies do not modify the results.
CONCLUSIONS
This is the largest study to date of sex differences in
outcomes after TAVR. Women had signiﬁcantly better
late survival despite higher rates of major bleeding,
vascular, and stroke complications. Given the natural
longer life expectancy of women, TAVR should be
even more cost effective in women than in men. If it
is conﬁrmed that conventional surgery has worse
outcomes in women than in men, these ﬁndings may
have signiﬁcant implications for future patient se-
lection for TAVR. However, the deﬁnitive answer
will be provided by ongoing trials comparingconventional surgery with TAVR in medium-risk pa-
tients, which may demonstrate that women can
beneﬁt earlier from TAVR than men.
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